<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Werewolf Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/werewolf-therapeutics-inc</link>
<description>Latest news and press releases for Werewolf Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 27 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/werewolf-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68357f2078dffbe2df0fae15.webp</url>
<title>Werewolf Therapeutics Inc</title>
<link>https://6ix.com/company/werewolf-therapeutics-inc</link>
</image>
<item>
<title>Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates</title>
<link>https://6ix.com/company/werewolf-therapeutics-inc/news/werewolf-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-corporate-updates</link>
<guid isPermaLink="true">https://6ix.com/company/werewolf-therapeutics-inc/news/werewolf-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-corporate-updates</guid>
<pubDate>Fri, 27 Mar 2026 04:00:00 GMT</pubDate>
<description>Company continues to evaluate strategic options to maximize shareholder value WATERTOWN, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc.</description>
</item>
<item>
<title>Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives</title>
<link>https://6ix.com/company/werewolf-therapeutics-inc/news/werewolf-therapeutics-announces-plan-to-explore-strategic-alternatives</link>
<guid isPermaLink="true">https://6ix.com/company/werewolf-therapeutics-inc/news/werewolf-therapeutics-announces-plan-to-explore-strategic-alternatives</guid>
<pubDate>Tue, 24 Feb 2026 21:09:00 GMT</pubDate>
<description>WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) (the “Company” or “Werewolf”), an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that the Company will explore a full range of strategic alternatives to advance its promising platform and drug development pipeline to maximize stockholder val</description>
</item>
<item>
<title>Werewolf Therapeutics Announces Pipeline and Business Updates</title>
<link>https://6ix.com/company/werewolf-therapeutics-inc/news/werewolf-therapeutics-announces-pipeline-business-130000079</link>
<guid isPermaLink="true">https://6ix.com/company/werewolf-therapeutics-inc/news/werewolf-therapeutics-announces-pipeline-business-130000079</guid>
<pubDate>Thu, 18 Dec 2025 13:00:00 GMT</pubDate>
<description>WTX-124 initial Phase 1b expansion arm data showed 30% overall response rate as a monotherapy in a defined subset of post-ICI advanced or metastatic cutaneous melanoma patients, with potential best-in-class tolerability profileWTX-330 Phase 1b/2 trial initial data demonstrated additional evidence of antitumor activity and highly favorable tolerability profile, building upon monotherapy activity demonstrated in first-in-human Phase 1 clinical trialAdditional Phase 1/1b data update for WTX-124 and</description>
</item>
<item>
<title>Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting</title>
<link>https://6ix.com/company/werewolf-therapeutics-inc/news/werewolf-therapeutics-presents-data-expanding-140000917</link>
<guid isPermaLink="true">https://6ix.com/company/werewolf-therapeutics-inc/news/werewolf-therapeutics-presents-data-expanding-140000917</guid>
<pubDate>Fri, 07 Nov 2025 14:00:00 GMT</pubDate>
<description>Novel INDUCER™ T Cell Engager Platform designed to mitigate systemic toxicities Sequential dosing of INDUKINE™ molecules in preclinical model showed potent antitumor activity with improved safety First-in-kind real-time pharmacokinetic data in a mouse tumor model confirmed WTX-124 selective activation in tumors, sparing healthy tissue WATERTOWN, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical compa</description>
</item>
<item>
<title>Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/werewolf-therapeutics-inc/news/werewolf-therapeutics-reports-third-quarter-120000683</link>
<guid isPermaLink="true">https://6ix.com/company/werewolf-therapeutics-inc/news/werewolf-therapeutics-reports-third-quarter-120000683</guid>
<pubDate>Tue, 04 Nov 2025 12:00:00 GMT</pubDate>
<description>– Update on WTX-124 Phase 1/1b clinical trial interim data and End of Phase 1 meeting with the U.S. Food & Drug Administration (FDA) is expected to be provided later in the fourth quarter of 2025 – – Update on Phase 1b/2 clinical trial of WTX-330 and potential further development plan is expected to be provided later in the fourth quarter of 2025 – – WTX-1011, Company’s first INDUCER™ T-cell engager development candidate targeting STEAP1, continues IND-enabling studies – WATERTOWN, Mass., Nov. 0</description>
</item>
<item>
<title>Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer</title>
<link>https://6ix.com/company/werewolf-therapeutics-inc/news/werewolf-therapeutics-receives-fast-track-120000648</link>
<guid isPermaLink="true">https://6ix.com/company/werewolf-therapeutics-inc/news/werewolf-therapeutics-receives-fast-track-120000648</guid>
<pubDate>Wed, 08 Oct 2025 12:00:00 GMT</pubDate>
<description>Fast Track Designation underscores the promise of Werewolf’s INDUKINE™ platform WATERTOWN, Mass., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that the Company has received Fast Track Designation for the use of WTX-124 for the potential treatment of patients with</description>
</item>
<item>
<title>Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting</title>
<link>https://6ix.com/company/werewolf-therapeutics-inc/news/werewolf-therapeutics-present-posters-society-130000865</link>
<guid isPermaLink="true">https://6ix.com/company/werewolf-therapeutics-inc/news/werewolf-therapeutics-present-posters-society-130000865</guid>
<pubDate>Fri, 03 Oct 2025 13:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that three posters will be presented at the upcoming Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting, taking place Nove</description>
</item>
<item>
<title>Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/werewolf-therapeutics-inc/news/werewolf-therapeutics-participate-upcoming-h-120000590</link>
<guid isPermaLink="true">https://6ix.com/company/werewolf-therapeutics-inc/news/werewolf-therapeutics-participate-upcoming-h-120000590</guid>
<pubDate>Tue, 02 Sep 2025 12:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer and Randi Isaacs, M.D., Chief Medical Officer, both of Werewolf Th</description>
</item>
<item>
<title>Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/werewolf-therapeutics-inc/news/werewolf-therapeutics-reports-second-quarter-110000295</link>
<guid isPermaLink="true">https://6ix.com/company/werewolf-therapeutics-inc/news/werewolf-therapeutics-reports-second-quarter-110000295</guid>
<pubDate>Thu, 14 Aug 2025 11:00:00 GMT</pubDate>
<description>– WTX-124 Phase 1/1b clinical trial on track for interim data readout in the fourth quarter of 2025, including patients in both the monotherapy and combination expansion arms of cutaneous melanoma and renal cell carcinoma – – Planning to engage with U.S. Food & Drug Administration (FDA) in the second half of 2025 to discuss potential registrational pathways for WTX-124 in advanced or metastatic cutaneous melanoma – – Phase 1b/2 clinical trial of WTX-330 is actively enrolling, with anticipated de</description>
</item>
<item>
<title>Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit</title>
<link>https://6ix.com/company/werewolf-therapeutics-inc/news/werewolf-therapeutics-participate-kidneycan-7th-120000882</link>
<guid isPermaLink="true">https://6ix.com/company/werewolf-therapeutics-inc/news/werewolf-therapeutics-participate-kidneycan-7th-120000882</guid>
<pubDate>Wed, 09 Jul 2025 12:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced Randi Isaacs, M.D., Chief Medical Officer, will speak at the upcoming KidneyCAN 7th Annual Kidney Cancer Research Summit taking place Ju</description>
</item>
<item>
<title>Werewolf Therapeutics to Participate in the BIO International Convention</title>
<link>https://6ix.com/company/werewolf-therapeutics-inc/news/werewolf-therapeutics-participate-bio-international-120000439</link>
<guid isPermaLink="true">https://6ix.com/company/werewolf-therapeutics-inc/news/werewolf-therapeutics-participate-bio-international-120000439</guid>
<pubDate>Thu, 12 Jun 2025 12:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced Randi Isaacs, M.D., Chief Medical Officer, will participate in a panel discussion at the upcoming BIO International Convention taking pl</description>
</item>
<item>
<title>Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference</title>
<link>https://6ix.com/company/werewolf-therapeutics-inc/news/werewolf-therapeutics-participate-upcoming-jefferies-120000369</link>
<guid isPermaLink="true">https://6ix.com/company/werewolf-therapeutics-inc/news/werewolf-therapeutics-participate-upcoming-jefferies-120000369</guid>
<pubDate>Thu, 29 May 2025 12:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer and Randi Isaacs, M.D., Chief Medical Officer, both of Werewolf Therapeutics, will participate in a fires</description>
</item>
<item>
<title>HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124</title>
<link>https://6ix.com/company/werewolf-therapeutics-inc/news/honorhealth-research-institute-patient-with-advanced-skin-cancer-in-remission-for-more-than-a-year-following-clinical-trial-of-werewolf-therapeutics-investigational-novel-conditionally-activated-il-2-pro-drug-wtx-124</link>
<guid isPermaLink="true">https://6ix.com/company/werewolf-therapeutics-inc/news/honorhealth-research-institute-patient-with-advanced-skin-cancer-in-remission-for-more-than-a-year-following-clinical-trial-of-werewolf-therapeutics-investigational-novel-conditionally-activated-il-2-pro-drug-wtx-124</guid>
<pubDate>Tue, 20 May 2025 20:01:00 GMT</pubDate>
<description>There are nearly 40,000 U.S. cases of cutaneous squamous cell carcinoma each year that advance to stages that are difficult to treat and life-threatening Skin Cancer Awareness Month in May shines a spotlight on the growing burden of advanced skin cancers The investigational drug is designed to be activated in the tumor microenvironment, including in cutaneous squamous cell carcinoma SCOTTSDALE, Ariz., May 20, 2025 (GLOBE NEWSWIRE) -- A common and unsightly skin cancer that can turn deadly has be</description>
</item>
<item>
<title>Werewolf Therapeutics to Participate in Hanson Wade’s 6th Annual Cytokine-Based Drug Development Summit</title>
<link>https://6ix.com/company/werewolf-therapeutics-inc/news/werewolf-therapeutics-participate-hanson-wade-120000702</link>
<guid isPermaLink="true">https://6ix.com/company/werewolf-therapeutics-inc/news/werewolf-therapeutics-participate-hanson-wade-120000702</guid>
<pubDate>Tue, 13 May 2025 12:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced Sameer Chopra, M.D., Ph.D., Vice President of Clinical Development, will speak during the Hanson Wade Cytokine-Based Drug Development Sum</description>
</item>
<item>
<title>Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/werewolf-therapeutics-inc/news/werewolf-therapeutics-reports-first-quarter-110000335</link>
<guid isPermaLink="true">https://6ix.com/company/werewolf-therapeutics-inc/news/werewolf-therapeutics-reports-first-quarter-110000335</guid>
<pubDate>Thu, 08 May 2025 11:00:00 GMT</pubDate>
<description>– WTX-124 Phase 1/1b clinical trial on track for data readouts and interactions with the FDA in the second half of the year – – First patient dosed in the Phase 1b/2 clinical trial of WTX-330, seeking to build on the clinical activity and tolerability demonstrated in the recently completed WTX-330 first-in-human Phase 1 trial – – Company announces development of its proprietary INDUCER™ T cell engager molecules; development candidate targeted by the end of the second quarter of 2025 – – Updated</description>
</item>
<item>
<title>Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting</title>
<link>https://6ix.com/company/werewolf-therapeutics-inc/news/werewolf-therapeutics-presents-preclinical-data-120500300</link>
<guid isPermaLink="true">https://6ix.com/company/werewolf-therapeutics-inc/news/werewolf-therapeutics-presents-preclinical-data-120500300</guid>
<pubDate>Mon, 05 May 2025 12:05:00 GMT</pubDate>
<description>- Data reveal WTX-921 is efficacious in a mouse colitis model, resulting in reduced tissue damage and inflammatory cytokine production - - Findings offer a more detailed understanding of WTX-921’s anti-inflammatory impact on the immune landscape in the inflamed colon - WATERTOWN, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutic</description>
</item>
<item>
<title>Werewolf Therapeutics to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/werewolf-therapeutics-inc/news/werewolf-therapeutics-participate-upcoming-investor-120000414</link>
<guid isPermaLink="true">https://6ix.com/company/werewolf-therapeutics-inc/news/werewolf-therapeutics-participate-upcoming-investor-120000414</guid>
<pubDate>Mon, 05 May 2025 12:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that management will participate in the following upcoming investor conferences in the month of May: The Citizens Life Sciences Conferenc</description>
</item>
<item>
<title>Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer</title>
<link>https://6ix.com/company/werewolf-therapeutics-inc/news/werewolf-therapeutics-appoints-steven-bloom-120000791</link>
<guid isPermaLink="true">https://6ix.com/company/werewolf-therapeutics-inc/news/werewolf-therapeutics-appoints-steven-bloom-120000791</guid>
<pubDate>Thu, 17 Apr 2025 12:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced the appointment of Steven Bloom as Chief Business Officer. Mr. Bloom brings more than 35 years of experience in the life sciences indus</description>
</item>
<item>
<title>Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/werewolf-therapeutics-inc/news/werewolf-therapeutics-present-24th-annual-120000132</link>
<guid isPermaLink="true">https://6ix.com/company/werewolf-therapeutics-inc/news/werewolf-therapeutics-present-24th-annual-120000132</guid>
<pubDate>Mon, 31 Mar 2025 12:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer and Randi Isaacs, M.D., Chief Medical Officer, both of Werewolf Th</description>
</item>
<item>
<title>Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/werewolf-therapeutics-inc/news/werewolf-therapeutics-reports-fourth-quarter-110000181</link>
<guid isPermaLink="true">https://6ix.com/company/werewolf-therapeutics-inc/news/werewolf-therapeutics-reports-fourth-quarter-110000181</guid>
<pubDate>Tue, 11 Mar 2025 11:00:00 GMT</pubDate>
<description>– Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination with pembrolizumab expected by the end of the first half and the second half of 2025, respectively – – Plan to meet with the FDA in the second half of 2025 to discuss potential registrational pathways for both monotherapy and combination therapy for WTX-124 in select indications – – Interim data from Phase 1/1b clinical trial of WTX-124 as monotherapy and</description>
</item>
</channel>
</rss>